Skystar Bio-Pharmaceutical Provides Update to Its Patent Portfolio - Seite 2

Skystar is currently waiting for the SIPO office to issue the Company physical patent certificates for the two products. In addition, Skystar has applied to China's SIPO and was issued two additional patent application numbers 2014100550285 and 2014100559364, pending completion of the SIPO patent application review.

Finally, the Company's previously purchased exclusive patented aquaculture vaccine technology from China's Fourth Military Medical University ("FMMU") expired in December 2011. Under the FMMU collaborative research and development agreement the Company was granted Company exclusive rights to sell and market the aquaculture vaccine through 2020, the Company retains know-how for the production line for the vaccine. In collaboration with FMMU, Skystar is in a position to produce the first vaccine in China designed to prevent and treat certain bacterial infection and diseases in marine life without causing harmful side effects. Based on its first-to-market status, China's Ministry of Agriculture has issued a Grade I Veterinary Certificate for this vaccine.

Commenting on these developments, Mr. Weibing Lu, Chairman and CEO of the Company, said, "We are pleased to have received patent protection from China's SIPO for these two products. It is Skystar's goal to continue to introduce commonly applied Western methodologies, medicines and supplements to the animal husbandry ecosystem within China. In turn, the Company hopes to be part of the change in China directed at protecting the nation's food source by standardizing and modernizing the ways in which the animal husbandry industry operates."

To be added to the Company's email distribution for future news releases, please send your request to [e-mail].

About Skystar Bio-Pharmaceutical Company

Skystar is a China-based developer, manufacturer and distributor of veterinary healthcare and medical care products. Skystar has four product lines: veterinary medicines, probiotics, vaccines and feed additives formulated and packaged in house across several modern manufacturing and distributions facilities. Skystar's distribution network includes almost 3,000 distribution agents of which 360 are franchised stores with exclusivity agreements covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.